Obesity and type 2 diabetes: which patients are at risk?

被引:71
|
作者
Garber, A. J. [1 ,2 ,3 ]
机构
[1] Baylor Coll Med, Dept Med, Houston, TX 77030 USA
[2] Baylor Coll Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA
[3] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA
关键词
diabetes complications; glucose metabolism; insulin resistance; treatment guidelines; type; 2; diabetes; weight-loss therapy; IMPAIRED GLUCOSE-TOLERANCE; FASTING GLUCOSE; CARDIOVASCULAR-DISEASE; INSULIN-RESISTANCE; ADIPOSE-TISSUE; ECTOPIC FAT; WEIGHT-LOSS; PREVENTION PROGRAM; METABOLIC SYNDROME; RECEPTOR AGONISTS;
D O I
10.1111/j.1463-1326.2011.01536.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
An estimated 72.5 million American adults are obese, and the growing US obesity epidemic is responsible for substantial increase in morbidity and mortality, as well as increased health care costs. Obesity results from a combination of personal and societal factors, but is often viewed as a character flaw rather than a medical condition. This leads to stigma and discrimination towards obese individuals and decreases the likelihood of effective intervention. Conditions related to obesity are increasingly common, such as metabolic syndrome, impaired fasting glucose (IFG) and impaired glucose tolerance (IGT), all of which indicate high risk for type 2 diabetes (T2DM). This paper reviews the progression from obesity to diabetes, identifying physiological changes that occur along this path as well as opportunities for patient identification and disease prevention. Patients with prediabetes (defined as having IFG, IGT or both) and/or metabolic syndrome require interventions designed to preserve insulin sensitivity and beta-cell function, both of which start to deteriorate prior to T2DM diagnosis. Lifestyle modification, including both healthy eating choices and increased physical activity, is essential for weight management and diabetes prevention. Although sustained weight loss is often considered by patients and physicians as being impossible to achieve, effective interventions do exist. Specifically, the Diabetes Prevention Program (DPP) and programs modelled along its parameters have shown repeated successes, even with long-term maintenance. Recent setbacks in the development of medications for weight loss further stress the importance of lifestyle management. By viewing obesity as a metabolic disorder rather than a personal weakness, we can work with patients to address this increasingly prevalent condition and improve long-term health outcomes.
引用
收藏
页码:399 / 408
页数:10
相关论文
共 50 条
  • [1] Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes
    Després, JP
    DIABETES & METABOLISM, 2003, 29 (04) : S53 - S61
  • [2] Tools for Predicting the Risk of Type 2 Diabetes in Daily Practice
    Schwarz, P. E. H.
    Li, J.
    Lindstrom, J.
    Tuomilehto, J.
    HORMONE AND METABOLIC RESEARCH, 2009, 41 (02) : 86 - 97
  • [3] Obesity, type 2 diabetes mellitus and cardiovascular disease risk: an uptodate in the management of polycystic ovary syndrome
    Orio, Francesco
    Muscogiuri, Giovanna
    Nese, Cinar
    Palomba, Stefano
    Savastano, Silvia
    Tafuri, Domenico
    Colarieti, Giorgio
    La Sala, Giovanbattista
    Colao, Annamaria
    Yildiz, Bulent O.
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2016, 207 : 214 - 219
  • [4] Biomarkers in Type 2 diabetes: improving risk stratification with the PreDx® Diabetes Risk Score
    Kolberg, Janice A.
    Gerwien, Robert W.
    Watkins, Steve M.
    Wuestehube, Linda J.
    Urdea, Mickey
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2011, 11 (08) : 775 - 792
  • [5] The interplay between muscle mass decline, obesity, and type 2 diabetes
    Maliszewska, Katarzyna
    Adamska-Patruno, Edyta
    Kretowski, Adam
    POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ, 2019, 129 (11): : 809 - 816
  • [6] Sleep influences on obesity, insulin resistance, and risk of type 2 diabetes
    Reutrakul, Sirimon
    Van Cauter, Eve
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2018, 84 : 56 - 66
  • [7] Plasma calprotectin and its association with cardiovascular disease manifestations, obesity and the metabolic syndrome in type 2 diabetes mellitus patients
    Pedersen, Lise
    Nybo, Mads
    Poulsen, Mikael Kjaer
    Henriksen, Jan Erik
    Dahl, Jordi
    Rasmussen, Lars Melholt
    BMC CARDIOVASCULAR DISORDERS, 2014, 14
  • [8] Obesity, type 2 diabetes, and testosterone in ageing men
    Wittert, Gary
    Grossmann, Mathis
    REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, 2022, 23 (06) : 1233 - 1242
  • [9] Magnesium in Obesity, Metabolic Syndrome, and Type 2 Diabetes
    Piuri, Gabriele
    Zocchi, Monica
    Della Porta, Matteo
    Ficara, Valentina
    Manoni, Michele
    Zuccotti, Gian Vincenzo
    Pinotti, Luciano
    Maier, Jeanette A.
    Cazzola, Roberta
    NUTRIENTS, 2021, 13 (02) : 1 - 17
  • [10] Epigenetics and Type 2 Diabetes Risk
    Dhawan, Sangeeta
    Natarajan, Rama
    CURRENT DIABETES REPORTS, 2019, 19 (08)